A cancer-testing company’s telemedicine vendor, Grail Inc., on Friday mistakenly sent letters to 400 patients suggesting they had cancer.
According to ReutersGalleri, the company’s premier blood test for cancer diagnosis, aims to identify more than 50 different cancers before symptoms develop.
“GRAIL has confirmed that this issue was in no way related to or caused by false gallery laboratory test results,” the company, which is owned by San Diego-based biotechnology company Illumina Inc, said. Fox News Digital.
“The erroneous letter from PWNHealth was inadvertently triggered by an issue with its software configuration, which has now been disabled,” he added.
Greil claimed that it contacted patients as soon as it became aware of the issue and that no patient’s health information was exposed or compromised as a result.
Illumina is currently appealing regulatory orders in the US and EU that force it to sell Grail after it bypassed regulators to complete its acquisition of the cancer test maker.
According to the FTC, the $7.1 billion transaction would stifle innovation and competition in the U.S. market for life-saving cancer tests.
The revolutionary GALLERY test will actually “increase availability, affordability and profitability in the more than $44 billion multi-cancer screening market,” according to Illumina, which claimed in a press release in April.